Drugs / SRN001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07407543 | Jan → Oct 2026 expected | idiopathic pulmonary fibrosis | siRNAgen Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05984992 | Sep 2023 → Mar 2024 | idiopathic pulmonary fibrosis | siRNAgen Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRN001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07407543 ↗ |
| Action | Inhibit | “SRN-001 is designed to downregulate generating amphiregulin by RNA interference (RNAi).” NCT05984992 ↗ |
| Modality | Small interfering RNA (siRNA) | “novel small interfering RNA (siRNA) drug” NCT05984992 ↗ |
| Target | AREG | “Amphiregulin (AREG) is a growth factor involved in fibroblast proliferation and myofibroblast transformation which is the hallmark of fibrosis in lung and kidney tissues. AREG...” NCT07407543 ↗ |